Efficacy and tolerability of treatment with lacosamide: Postmarketing experience from the Middle East region
Affiliations
Affiliations
- Ibn Sina Hospital, Kuwait City, Kuwait.
- American Center for Psychiatry & Neurology, Abu Dhabi, United Arab Emirates.
- American University of Beirut Medical Center, Beirut, Lebanon. Electronic address: wn13@aub.edu.lb.
- American University of Beirut Medical Center, Beirut, Lebanon.
Abstract
Purpose: Lacosamide (LCM) was recently introduced in the Middle East. The aim of this study was to evaluate the safety, tolerability, and efficacy of LCM in patients with focal onset seizures and determine if our results are comparable with those derived from Western countries.
Methods: This is a retrospective analysis from two medical centers on consecutive patients diagnosed as having focal onset seizures and treated with add-on LCM. The primary efficacy variables were the 50% responder and seizure-free rates, and the secondary outcome variables included the percentages of patients who achieved seizure remission during the last 6-month follow-up period and the percentages of discontinuation due to lack of efficacy or tolerability.
Results: One hundred four patients with a mean age of 30.9 years and experiencing a mean of 9.4 seizures per month during baseline were included. The 50% responder rates were 69% and 70% at 6- and 24-month follow-ups, respectively. Patients concomitantly treated with a sodium channel blocker were less likely to achieve seizure remission during the last 6-month follow-up period while the early introduction of LCM resulted in a significantly higher likelihood of achieving such a remission. Eighty-eight percent of patients were still maintained on LCM at the last follow-up, and the most common adverse events consisted of dizziness and somnolence, double vision, and nausea/vomiting.
Conclusions: Our data show similar efficacy and tolerability to those reported from Western countries. Our results also substantiate the early introduction of LCM and support the dose reduction of baseline AED especially that of sodium channel blockers to minimize adverse events.
Keywords: Antiepileptic drugs; Lacosamide; Phase IV trial.
Similar articles
Hmaimess G, Sabbagh S, Dirani M, Hotait M, Beydoun AA, Nasreddine W.Seizure. 2020 Jul;79:75-79. doi: 10.1016/j.seizure.2020.04.016. Epub 2020 May 11.PMID: 32422546 Clinical Trial.
Neal A, D'Souza W, Hepworth G, Lawn N, Cook M, Nikpour A.Epilepsy Behav. 2018 Mar;80:25-32. doi: 10.1016/j.yebeh.2017.11.027. Epub 2018 Feb 3.PMID: 29396359
Foldvary-Schaefer N, Fong JS, Morrison S, Wang L, Bena J.Epilepsy Behav. 2016 Apr;57(Pt A):155-160. doi: 10.1016/j.yebeh.2016.02.007. Epub 2016 Mar 5.PMID: 26956629
Zaccara G, Giovannelli F, Maratea D, Fadda V, Verrotti A.Seizure. 2013 Sep;22(7):528-36. doi: 10.1016/j.seizure.2013.03.016. Epub 2013 Apr 25.PMID: 23623245 Review.
Brigo F, Bragazzi NL, Nardone R, Trinka E.Seizure. 2016 Nov;42:29-37. doi: 10.1016/j.seizure.2016.08.007. Epub 2016 Sep 24.PMID: 27710868 Review.
Cited by
Zhao T, Li HJ, Zhang HL, Feng J, Yu J, Wang TT, Sun Y, Yu LH.Ther Drug Monit. 2023 Feb 1;45(1):117-125. doi: 10.1097/FTD.0000000000001003. Epub 2023 Oct 8.PMID: 36253887 Free PMC article.
Yang C, Peng Y, Zhang L, Zhao L.Front Pharmacol. 2021 Sep 20;12:694381. doi: 10.3389/fphar.2021.694381. eCollection 2021.PMID: 34616294 Free PMC article.
Zhao T, Li HJ, Feng J, Zhang HL, Ting-Ting W, Ma L, Yu J, Zhao WB, Sun L, Yu LH, Sun Y.Ther Drug Monit. 2022 Jun 1;44(3):455-464. doi: 10.1097/FTD.0000000000000927. Epub 2021 Oct 5.PMID: 34610620 Free PMC article.